Break that down for us. You think the market is going to immediately give us credit for 2020 Remdesivir revenue AND slap a 7x PE on it (as though COVID will continue at 2020 levels for 7 years)?
$1.5 billion would be an extremely strong valuation for good phase 2 results. That's similar to what CYDY, Relief andHGEN enjoyed.Help me imagine where the other $13 billion comes from.